Factors influencing adherence to molecular therapies in haematology-oncology outpatients

Journal of Pharmacy Practice and Research

Volumn 36, Issue 2, 2006, Pages 115-118

  Larizza, Maria A ^c,d   Dooley, Michael J ^a   Stewart, Kay ^b   Kong, David C M ^b,c  

^a Department of Clinical Pharmacy ^*  (Australia)

^b MONASH UNIVERSITY   (Australia)

^c The Alfred   (Australia)

^d Pharmacy Department   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; THALIDOMIDE;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG MONITORING; ENVIRONMENTAL FACTOR; HEMATOLOGY; HOSPITAL SERVICE; HUMAN; MEDICAL LITERATURE; MOTIVATION; MULTIPLE MYELOMA; ONCOLOGY; OUTPATIENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERCEPTION; PRESCRIPTION; QUESTIONNAIRE; SOCIAL ENVIRONMENT;

EID: 33746153427     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2006.tb00584.x     Document Type: Article

References (16)

1. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with Interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
2. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-4.
3. Partridge A, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002; 94: 652-61.
4. Levine AM, Marks G, Chan K, Graham J, Selser JN, et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 1987; 5.
5. Haynes RB, Sackett DL, Gibson ES, Bernholz CD, Mukherjee J. Can simple clinical measurements detect patient noncompliance? Hypertension 1980; 2: 757.
6. Levine AM, Marks G, Chan K, Graham J, Selser JN, et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 1987; 5: 1469-76.
7. Lebovits AH, Schleifer SJ, Tanaka JS, Bhardwaj S, Messe MR. Patient noncompliance with self-administered chemotherapy. Cancer 1990; 65: 17-22.
8. Becker MH. Sociobehavioral determinants of compliance. In: Sackett DL, Haynes RB, editors. Compliance with therapeutic regimens. Baltimore: Johns Hopkins University Press; 1976. p. 40-50.
9. Wang PS, Knight E, Glynn RJ, Mogun H, Avorn J. Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Int Med. 2002; 17: 504-11.
10. Cleeland C. Measurement of pain by subjective report. In: Chapman CR, Loeser JD, editors. Issues of pain measurement: advances in pain research and therapy. New York: Raven Press; 1989. p. 391-403.
11. George J, Mackinnon A, Kong DCM, Stewart K. Development and validation of the Beliefs and Behaviour Questionnaire (BBQ). Patient Educ Couns 2006. In press.
12. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care 2000; 3: 255-66.
13. George J, Bailey MJ, Kong DCM, Stewart K. Development and validation of the Medication Regimen Complexity Index. Ann Pharmacother 2004; 38: 1369-76.
14. Morisky DE, Levine DW. Concurent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74.
15. Chesney AC. Factors affecting adherence to antiretroviral therapy. Clin Infec Dis 2000; 30 (suppl. 2): S171-S176.
16. Bailey JE, Somes GW, Graham RL. Risk factors for antihypertensive medication refill failure by patients under Medicaid managed care. Clin Ther 1996; 18: 1252-62.